New hope for bipolar depression? pramipexole trial targets anhedonia

NCT ID NCT07664852

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether pramipexole, a dopamine-boosting drug, can ease anhedonia (loss of pleasure) in people with bipolar depression. 126 participants will receive either pramipexole or a placebo alongside their usual mood stabilizer for 6 weeks. The study aims to improve mood and potentially reduce suicide risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

pramipexole

What this could lead to

If successful, this could provide a new treatment option for bipolar depression, potentially reducing suffering and lowering suicide risk.

What could go wrong

This is an early-stage Phase 3 trial with only 126 participants. Results may not confirm earlier promising findings, and pramipexole can cause side effects like nausea or dizziness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anhedonia bipolar depression bipolar disorder bipolar I disorder bipolar II disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Adult Psychiatry

    Lund, Skåne County, 22240, Sweden

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••